tetano
Editor, Senior Moderator
J Infect Chemother. 2018 May 31. pii: S1341-321X(18)30123-5. doi: 10.1016/j.jiac.2018.04.013. [Epub ahead of print]
[h=1]Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016/17 Japanese influenza season; comparison with the 2011/12 to 2015/16 seasons.[/h] Ikematsu H[SUP]1[/SUP], Kawai N[SUP]2[/SUP], Iwaki N[SUP]2[/SUP], Kashiwagi S[SUP]2[/SUP], Ishikawa Y[SUP]3[/SUP], Yamaguchi H[SUP]3[/SUP], Shiosakai K[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The duration of fever and symptoms after laninamivir octanoate hydrate (laninamivir) inhalation were investigated in the Japanese 2016/17 influenza season and the results were compared with those of the 2011/12 to 2015/16 seasons. A total of 1278 patients were evaluated for the duration of fever and symptoms in the six studied seasons. In the 2016/17 season, the influenza types/subtypes of the patients were 6 A (H1N1)pdm09 (2.9%), 183 A (H3N2) (87.6%), and 20 B (9.6%). The respective median durations of fever for A (H1N1)pdm09, A (H3N2), and B were 38.0, 33.0, and 38.5 h, without significant difference (p = 0.9201), and the median durations of symptoms were 86.5, 73.0, and 99.0 h, with significant difference (p = 0.0342). The median durations of fever and symptoms after laninamivir inhalation were quite consistent for the six studied seasons for A (H1N1)pdm09, A (H3N2), and B, without any significant differences. The percentage of patients with unresolved fever patients displayed a similar pattern through the six studied seasons for all these virus types. There was no significant difference in the duration of fever or symptoms between the Victoria and Yamagata lineages in the 2016/17 season and those of the previous studied seasons. Over the seasons tested, ten adverse drug reactions (ADRs) were reported from 1341 patients. The most frequent ADR was diarrhea and all ADRs were self-resolving and not serious. These results indicate the continuing clinical effectiveness of laninamivir against influenza A (H1N1)pdm09, A (H3N2), and B, with no safety issues.
[h=4]KEYWORDS:[/h] Fever; Influenza; Laninamivir; Neuraminidase inhibitor; Symptom
PMID: 29861186 DOI: 10.1016/j.jiac.2018.04.013
[h=1]Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016/17 Japanese influenza season; comparison with the 2011/12 to 2015/16 seasons.[/h] Ikematsu H[SUP]1[/SUP], Kawai N[SUP]2[/SUP], Iwaki N[SUP]2[/SUP], Kashiwagi S[SUP]2[/SUP], Ishikawa Y[SUP]3[/SUP], Yamaguchi H[SUP]3[/SUP], Shiosakai K[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The duration of fever and symptoms after laninamivir octanoate hydrate (laninamivir) inhalation were investigated in the Japanese 2016/17 influenza season and the results were compared with those of the 2011/12 to 2015/16 seasons. A total of 1278 patients were evaluated for the duration of fever and symptoms in the six studied seasons. In the 2016/17 season, the influenza types/subtypes of the patients were 6 A (H1N1)pdm09 (2.9%), 183 A (H3N2) (87.6%), and 20 B (9.6%). The respective median durations of fever for A (H1N1)pdm09, A (H3N2), and B were 38.0, 33.0, and 38.5 h, without significant difference (p = 0.9201), and the median durations of symptoms were 86.5, 73.0, and 99.0 h, with significant difference (p = 0.0342). The median durations of fever and symptoms after laninamivir inhalation were quite consistent for the six studied seasons for A (H1N1)pdm09, A (H3N2), and B, without any significant differences. The percentage of patients with unresolved fever patients displayed a similar pattern through the six studied seasons for all these virus types. There was no significant difference in the duration of fever or symptoms between the Victoria and Yamagata lineages in the 2016/17 season and those of the previous studied seasons. Over the seasons tested, ten adverse drug reactions (ADRs) were reported from 1341 patients. The most frequent ADR was diarrhea and all ADRs were self-resolving and not serious. These results indicate the continuing clinical effectiveness of laninamivir against influenza A (H1N1)pdm09, A (H3N2), and B, with no safety issues.
[h=4]KEYWORDS:[/h] Fever; Influenza; Laninamivir; Neuraminidase inhibitor; Symptom
PMID: 29861186 DOI: 10.1016/j.jiac.2018.04.013